CX 2026 Registration
CX Executive Board
CX 2026 Programme
CX 2026 – The 48th Charing Cross Symposium
The Charing Cross (CX) Symposium continues to set the standard in vascular and endovascular education, shaping the future of practice worldwide. CX 2026 marked the final chapter of our current three-year cycle, designed to spark debate on the biggest controversies in the field. Our distinguished faculty of global experts critically examined the evidence, exchanged perspectives, and worked towards building consensus on the issues that matter most.
Consensus was the defining theme for CX 2026. We welcomed an international community of specialists, educators, and innovators to tackle the pressing challenges in vascular and endovascular medicine—challenges that directly impact patient outcomes and clinical decision-making.
In 2024, CX found a new home at ExCeL London, unlocking fresh opportunities for immersive, hands-on learning. The expanded workshop programme has gone from strength to strength, offering delegates practical skills alongside groundbreaking evidence and innovation. In 2026, we returned once again to London’s premier conference and exhibition venue to deliver an agenda packed with cutting-edge science, expert debate, and future-shaping education.
Stay connected—sign up for the CX Newsletter and be the first to hear the latest updates.
CX Co-Chairs
Latest CX news
EVAS is associated with a reduction in all-cause mortality
EVAS is associated with a reduction in all-cause mortality Marc Schermerhorn, Boston, United States
Podium 1st: Lutonix AV IDE interim 24 month update
Podium 1st: Lutonix AV IDE interim 24 month update Kate Steiner, Stevenage, United Kingdom
“Promising” initial results for sirolimus-eluting bioresorbable scaffold in DESappear trial
Andrew Holden The sirolimus-eluting bioresorbable peripheral scaffold system (Prava; Elixir Medical) is designed to treat stenoses and occlusion in the superficial femoral artery. Prava was first implanted in October 2016 and will [...]




